This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (281)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Asthma  • Allergy  • Alert me on articles by topic

A Multicenter, Randomized, Double-blind Trial

Theodore F. Reiss, MD; Paul Chervinsky, MD; Robert J. Dockhorn, MD; Sumiko Shingo, MS; Beth Seidenberg, MD; Thomas B. Edwards, MD; for the Montelukast Clinical Research Study Group

Arch Intern Med. 1998;158:1213-1220.

Objectives  To determine the clinical effect of oral montelukast sodium, a leukotriene receptor antagonist, in asthmatic patients aged 15 years or more.

Design  Randomized, multicenter, double-blind, placebo-controlled, parallel-group study. A 2-week, single-blind, placebo run-in period was followed by a 12-week, double-blind treatment period (montelukast sodium, 10 mg, or matching placebo, once daily at bedtime) and a 3-week, double-blind, washout period.

Setting/Patients  Fifty clinical centers randomly allocated 681 patients with chronic, stable asthma to receive placebo or montelukast after demonstrating a forced expiratory volume in 1 second 50% to 85% of the predicted value, at least a 15% improvement in forced expiratory volume in 1 second (absolute value) after inhaled -agonist administration, a minimal predefined level of daytime asthma symptoms, and inhaled -agonist use. Twenty-three percent of the patients used concomitant inhaled corticosteroids.

Primary End Points  Forced expiratory volume in 1 second and daytime asthma symptoms.

Results  Montelukast improved airway obstruction (forced expiratory volume in 1 second, morning and evening peak expiratory flow rate) and patient-reported end points (daytime asthma symptoms, "as-needed" -agonist use, nocturnal awakenings) (P<.001 compared with placebo). Montelukast provided near-maximal effect in these end points within the first day of treatment. Tolerance and rebound worsening of asthma did not occur. Montelukast improved outcome end points, including asthma exacerbations, asthma control days (P<.001 compared with placebo), and decreased peripheral blood eosinophil counts (P<.001 compared with placebo). The incidence of adverse events and discontinuations from therapy were similar in the montelukast and placebo groups.

Conclusions  Montelukast, compared with placebo, significantly improved asthma control during a 12-week treatment period. Montelukast was generally well tolerated, with an adverse event profile comparable with that of placebo.

From the Departments of Pulmonary/Immunology (Drs Reiss and Seidenberg) and Biostatistics (Ms Shingo), Merck Research Laboratories, Rahway, NJ; NE Research Center, Inc, North Dartmouth, Mass (Dr Chervinsky); International Medical Technology Consultants Inc, Prairie Village, Kan (Dr Dockhorn); and Allergy and Asthma Center, Albany Medical Center, Albany, NY (Dr Edwards).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Montelukast inhibition of resting and GM-CSF-stimulated eosinophil adhesion to VCAM-1 under flow conditions appears independent of cysLT1R antagonism
Robinson et al.
J. Leukoc. Biol. 2008;83:1522-1529.
ABSTRACT | FULL TEXT  

Global strategy for asthma management and prevention: GINA executive summary
Bateman et al.
Eur Respir J 2008;31:143-178.
ABSTRACT | FULL TEXT  

Leukotrienes
Peters-Golden and Henderson
NEJM 2007;357:1841-1854.
FULL TEXT  

Montelukast vs. Inhaled Low-Dose Budesonide as Monotherapy in the Treatment of Mild Persistent Asthma: A Randomized Double Blind Controlled Trial
Kumar et al.
J Trop Pediatr 2007;53:325-330.
ABSTRACT | FULL TEXT  

Smoking Affects Response to Inhaled Corticosteroids or Leukotriene Receptor Antagonists in Asthma
Lazarus et al.
Am. J. Respir. Crit. Care Med. 2007;175:783-790.
ABSTRACT | FULL TEXT  

Short-Course Montelukast for Intermittent Asthma in Children: A Randomized Controlled Trial
Robertson et al.
Am. J. Respir. Crit. Care Med. 2007;175:323-329.
ABSTRACT | FULL TEXT  

An oral selective M3 cholinergic receptor antagonist in COPD
Lu et al.
Eur Respir J 2006;28:772-780.
ABSTRACT | FULL TEXT  

Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children
de Benedictis et al.
Eur Respir J 2006;28:291-295.
ABSTRACT | FULL TEXT  

Pharmacokinetics and safety of montelukast in children aged 3 to 6 months.
Knorr et al.
J Clin Pharmacol 2006;46:620-627.
ABSTRACT | FULL TEXT  

Influence of body mass index on the response to asthma controller agents.
Peters-Golden et al.
Eur Respir J 2006;27:495-503.
ABSTRACT | FULL TEXT  

Leukotriene receptor antagonists - an update
DTB 2005;43:85-88.
ABSTRACT | FULL TEXT  

Effect of Montelukast on Exhaled Leukotrienes and Quality of Life in Asthmatic Patients
Biernacki et al.
Chest 2005;128:1958-1963.
ABSTRACT | FULL TEXT  

Montelukast, Compared With Fluticasone, for Control of Asthma Among 6- to 14-Year-Old Patients With Mild Asthma: The MOSAIC Study
Garcia Garcia et al.
Pediatrics 2005;116:360-369.
ABSTRACT | FULL TEXT  

Cysteinyl Leukotrienes in Allergic Inflammation: Strategic Target for Therapy
Busse and Kraft
Chest 2005;127:1312-1326.
ABSTRACT | FULL TEXT  

Montelukast Reduces Asthma Exacerbations in 2- to 5-Year-Old Children with Intermittent Asthma
Bisgaard et al.
Am. J. Respir. Crit. Care Med. 2005;171:315-322.
ABSTRACT | FULL TEXT  

Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast
Jayaram et al.
Thorax 2005;60:100-105.
ABSTRACT | FULL TEXT  

Tapering Dose of Inhaled Budesonide in Subjects with Mild-to-Moderate Persistent Asthma Treated with Montelukast: A 16-Week Single-Blind Randomized Study
Riccioni et al.
Annals of Clinical & Laboratory Science 2005;35:285-289.
ABSTRACT | FULL TEXT  

Zafirlukast Treatment for Acute Asthma: Evaluation in a Randomized, Double-Blind, Multicenter Trial
Silverman et al.
Chest 2004;126:1480-1489.
ABSTRACT | FULL TEXT  

Pharmacological Management to Reduce Exacerbations in Adults With Asthma: A Systematic Review and Meta-analysis
Sin et al.
JAMA 2004;292:367-376.
ABSTRACT | FULL TEXT  

Zafirlukast for severe recurrent vulvovaginal candidiasis: an open label pilot study
White et al.
Sex. Transm. Infect. 2004;80:219-222.
ABSTRACT | FULL TEXT  

Effect of Montelukast and Fluticasone Propionate on Airway Mucosal Blood Flow in Asthma
Mendes et al.
Am. J. Respir. Crit. Care Med. 2004;169:1131-1134.
ABSTRACT | FULL TEXT  

Transgenic smooth muscle expression of the human CysLT1 receptor induces enhanced responsiveness of murine airways to leukotriene D4
Yang et al.
Am. J. Physiol. Lung Cell. Mol. Physiol. 2004;286:L992-L1001.
ABSTRACT | FULL TEXT  

Pharmacokinetics of Montelukast in Asthmatic Patients 6 to 24 Months Old
Migoya et al.
J Clin Pharmacol 2004;44:487-494.
ABSTRACT | FULL TEXT  

Pharmacological Treatment of Airway Remodeling: Inhaled Corticosteroids or Antileukotrienes?
Riccioni et al.
Annals of Clinical & Laboratory Science 2004;34:138-142.
ABSTRACT | FULL TEXT  

Leukotriene Modifier Use and Asthma Severity: How Is a New Medication Being Used by Adults With Asthma?
Snyder et al.
Arch Intern Med 2004;164:617-622.
ABSTRACT | FULL TEXT  

Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation
Green et al.
Thorax 2004;59:100-104.
ABSTRACT | FULL TEXT  

Ethical Assessment of Clinical Asthma Trials Including Children Subjects
Coffey et al.
Pediatrics 2004;113:87-94.
ABSTRACT | FULL TEXT  

Leukotrienes, Sphingolipids, and Leukocyte Trafficking
Yopp et al.
J. Immunol. 2003;171:5-10.
FULL TEXT  

Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma
Vaquerizo et al.
Thorax 2003;58:204-210.
ABSTRACT | FULL TEXT  

Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma
Price et al.
Thorax 2003;58:211-216.
ABSTRACT | FULL TEXT  

Effect of the Addition of Montelukast to Inhaled Fluticasone Propionate on Airway Inflammation
O'Sullivan et al.
Am. J. Respir. Crit. Care Med. 2003;167:745-750.
ABSTRACT | FULL TEXT  

A Randomized Controlled Trial of Intravenous Montelukast in Acute Asthma
Camargo et al.
Am. J. Respir. Crit. Care Med. 2003;167:528-533.
ABSTRACT | FULL TEXT  

Eosinophilic oesophagitis: a novel treatment using Montelukast
Attwood et al.
Gut 2003;52:181-185.
ABSTRACT | FULL TEXT  

Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone
Baumgartner et al.
Eur Respir J 2003;21:123-128.
ABSTRACT | FULL TEXT  

Variability and lack of predictive ability of asthma end-points in clinical trials
Zhang et al.
Eur Respir J 2002;20:1102-1109.
ABSTRACT | FULL TEXT  

Correlation Between Cysteinyl Leukotriene Release From Leukocytes and Clinical Response to a Leukotriene Inhibitor
Terashima et al.
Chest 2002;122:1566-1570.
ABSTRACT | FULL TEXT  

Characterization of Mouse Cysteinyl Leukotriene Receptors mCysLT1 and mCysLT2. DIFFERENTIAL PHARMACOLOGICAL PROPERTIES AND TISSUE DISTRIBUTION
Ogasawara et al.
J. Biol. Chem. 2002;277:18763-18768.
ABSTRACT | FULL TEXT  

Reduction of Eosinophilic Inflammation in the Airways of Patients With Asthma Using Montelukast
Minoguchi et al.
Chest 2002;121:732-738.
ABSTRACT | FULL TEXT  

Marginal Utility of Montelukast for Persistent Asthma
Mathison and Koziol
Chest 2002;121:334-337.
ABSTRACT | FULL TEXT  

Improvement of Aspirin-Intolerant Asthma by Montelukast, a Leukotriene Antagonist . A Randomized, Double-Blind, Placebo-Controlled Trial
DAHLEN et al.
Am. J. Respir. Crit. Care Med. 2002;165:9-14.
ABSTRACT | FULL TEXT  

Comparison of Fluticasone Propionate-Salmeterol Combination Therapy and Montelukast in Patients Who Are Symptomatic on Short-acting beta 2-Agonists Alone
CALHOUN et al.
Am. J. Respir. Crit. Care Med. 2001;164:759-763.
ABSTRACT | FULL TEXT  

Montelukast, a Leukotriene Receptor Antagonist, for the Treatment of Persistent Asthma in Children Aged 2 to 5 Years
Knorr et al.
Pediatrics 2001;108:e48-48.
ABSTRACT | FULL TEXT  

Salmeterol Powder Provides Significantly Better Benefit Than Montelukast in Asthmatic Patients Receiving Concomitant Inhaled Corticosteroid Therapy
Fish et al.
Chest 2001;120:423-430.
ABSTRACT | FULL TEXT  

The Anti-inflammatory Effects of Leukotriene-Modifying Drugs and Their Use in Asthma
Salvi et al.
Chest 2001;119:1533-1546.
ABSTRACT | FULL TEXT  

Montelukast and Churg-Strauss syndrome
LIPWORTH et al.
Thorax 2001;56:244-244.
FULL TEXT  

Correlation of airway obstruction and patient-reported endpoints in clinical studies
Shingo et al.
Eur Respir J 2001;17:220-224.
ABSTRACT | FULL TEXT  

Leukotriene Modifiers in Pediatric Asthma Management
Bisgaard
Pediatrics 2001;107:381-390.
ABSTRACT | FULL TEXT  

Leukotriene receptor antagonist therapy
Dempsey
Postgrad. Med. J. 2000;76:767-773.
ABSTRACT | FULL TEXT  

Antiasthmatic Effects of Mediator Blockade versus Topical Corticosteroids in Allergic Rhinitis and Asthma
WILSON et al.
Am. J. Respir. Crit. Care Med. 2000;162:1297-1301.
ABSTRACT | FULL TEXT  

Montelukast, a Leukotriene Receptor Antagonist, in Combination With Loratadine, a Histamine Receptor Antagonist, in the Treatment of Chronic Asthma
Reicin et al.
Arch Intern Med 2000;160:2481-2488.
ABSTRACT | FULL TEXT  

Leukotriene Receptor Antagonists and Synthesis Inhibitors Reverse Survival in Eosinophils of Asthmatic Individuals
LEE et al.
Am. J. Respir. Crit. Care Med. 2000;161:1881-1886.
ABSTRACT | FULL TEXT  

Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials
Barnes and Miller
Thorax 2000;55:478-483.
ABSTRACT | FULL TEXT  

Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients
Dockhorn et al.
Thorax 2000;55:260-265.
ABSTRACT | FULL TEXT  

From Bench to Bedside . The Hurdles of Discovering a New Leukotriene Receptor Antagonist
RODGER
Am. J. Respir. Crit. Care Med. 2000;161:S7-10.
FULL TEXT  

Effects of Antileukotrienes in the Treatment of Asthma
BARNES
Am. J. Respir. Crit. Care Med. 2000;161:S73-76.
FULL TEXT  

Antileukotriene Therapy . Future Directions
HOLGATE and SAMPSON
Am. J. Respir. Crit. Care Med. 2000;161:S147-153.
FULL TEXT  

Montelukast Added to Inhaled Beclomethasone in Treatment of Asthma
LAVIOLETTE et al.
Am. J. Respir. Crit. Care Med. 1999;160:1862-1868.
ABSTRACT | FULL TEXT  

Leukotriene-receptor antagonists and related compounds
CMAJ 1999;161:s31-34.
FULL TEXT  

NO in Exhaled Air of Asthmatic Children Is Reduced by the Leukotriene Receptor Antagonist Montelukast
BISGAARD et al.
Am. J. Respir. Crit. Care Med. 1999;160:1227-1231.
ABSTRACT | FULL TEXT  

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients
Löfdahl et al.
BMJ 1999;319:87-90.
ABSTRACT | FULL TEXT  

Oral Montelukast, Inhaled Beclomethasone, and Placebo for Chronic Asthma: A Randomized, Controlled Trial
Malmstrom et al.
ANN INTERN MED 1999;130:487-495.
ABSTRACT | FULL TEXT  

Fortnightly review: Modern drug treatment of chronic asthma
Lipworth
BMJ 1999;318:380-384.
FULL TEXT  

The Emerging Role of Leukotriene Antagonists in Asthma Therapy
Lipworth
Chest 1999;115:313-316.
FULL TEXT  

Treatment of Asthma with Drugs Modifying the Leukotriene Pathway
Drazen et al.
NEJM 1999;340:197-206.
FULL TEXT  

Antileukotriene Drugs in the Management of Asthma
Wenzel
JAMA 1998;280:2068-2069.
FULL TEXT  

Inflammatory Mediators of Asthma: An Update
Barnes et al.
Pharmacol. Rev. 1998;50:515-596.
ABSTRACT | FULL TEXT  

{blacktriangledown}Montelukast and {blacktriangledown}zafirlukast in asthma
DTB 1998;36:65-68.
ABSTRACT | FULL TEXT  

Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction
Leff et al.
NEJM 1998;339:147-152.
ABSTRACT | FULL TEXT